

APR 29 2002

COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

00398/502003

Serial No.

10/021,952

Applicant

Andrew G. Plaut et al.

Filing Date

December 13, 2001

Group

1653


IDS Filed

April 18, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))


U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,304,633	04/19/94	Tomita et al.			
	5,565,425	10/15/96	Yamamoto et al.			
	5,725,864	03/10/98	Yamamoto et al.			
	5,834,424	11/10/98	Valenti et al.			
	5,849,885	12/15/98	Nuyens et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Arnold et al., "Bactericidal activity of human lactoferrin: Sensitivity of a variety of microorganisms," Infection and Immunity 28:893-898 (1980)
✓	Bellamy et al., "Identification of the bactericidal domain of lactoferrin," Biochimica et Biophysica Acta 1121:130-136 (1992)
✓	Dalmastri et al., "Enhanced antimicrobial activity of lactoferrin by binding to the bacterial surface," Microbiologica 11:225-230 (1988)
	Ellison III and Giehl, "Killing of gram-negative bacteria by lactoferrin and lysozyme," J. Clin. Invest. 88:1080-1091 (1991)
✓	Ellison III et al., "Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin," Infection and Immunity 56:2774-2781 (1988)
✓	Ellison III, "Lactoferrin and transferrin damage of the gram-negative outer membrane is modulated by Ca ²⁺ and Mg ²⁺ ," J. Gen. Microbiol. 136:1437-1446 (1990)
✓	Ellison III, "The effects of lactoferrin on gram-negative bacteria," Lactoferrin: Structure and Function, Edited by Hutchens et al., Plenum Press, New York, pp. 71-90 (1994)

EXAMINER

DATE CONSIDERED

8/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED

MAY 01 2002



COPY OF PAPERS
ORIGINALLY FILED

Sheet 1 of 1

TECH CENTER 1600/2900

MAY 01 2002

RECEIVED

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

00398/502003

Serial No.

10/021,952

Applicant

Andrew G. Plaut et al.

Filing Date

December 13, 2001

Group

1653

IDS Filed

April 18, 2002

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
JD	WO 97/05884	2/20/97	PCT			
JD	JP 03 220130		Japan (Abstract)			


OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

JD	Qui et al., "Human Milk Lactoferrin extracts the IgA protease precursor from the outer membrane of growing heamophilus influenzae cells," Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, vol. 35.
JD	Wittler et al., "Neutralization of Streptococcus sanguis IgA-1 protease by lactoferrin and transferrin," Abstract, Journal of Dental Research and Meeting Info: Joint Meeting of the International Association for Dental Research, the American Association of Dental Research, and the Canadian Association of Dental Research.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



COPY OF PAPERS
ORIGINALLY FILED

Sheet 2 of 2

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00398/502002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	09/289,997
(37 CFR §1.98(b))		Applicant	Andrew G. Plaut et al.
		Filing Date	December 13, 2001
		Group	1653
		IDS Filed	April 18, 2002
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
✓	Henderson et al., "The great escape: structure and function of the autotransporter proteins," Trends Microbiol. 6:370-380 (1998)		
✓	Hoek et al., "Antibacterial activity of bovine lactoferrin-derived peptides," Antimicrobial Agents and Chemotherapy 41:54-59 (1997)		
	Jose et al., "Common structural features of IgA1 protease-like outer membrane protein autotransporters," MicroCorrespondence 18(2):378-380 (1995)		
	Lee et al., "The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets," Infection and Immunity 66:1421-1426 (1998)		
	Legrand et al., "Evidence for interactions between the 30 kDa N- and 50 kDa C-terminal tryptic fragments of human lactotransferrin," Biochem. J. 236:839-844 (1986)		
✓	Lonnderdal and Iyer, "Lactoferrin: Molecular structure and biological function," Annu. Rev. Nutr. 15:93-110 (1995)		
	Qiu et al., "Human milk lactoferrin inactivates two putative colonization factors expressed by haemophilus influenzae," Proc. Natl. Acad. Sci. USA 95:12641-12646 (1998)		
	Stowell et al., "Expression of cloned human lactoferrin in baby-hamster kidney cells," Biochem. J. 276:349-355 (1991)		
✓	Tomita et al., "A review: The active peptide of lactoferrin," Acta Paediatrica Japonica 36:585-591 (1994)		
	Tomita et al., "Antimicrobial peptides of lactoferrin," Lactoferrin: Structure and Function, Ed. T.W. Hutchens et al., Plenum Press, New York, pp. 209-218 (1994)		
✓	Yamauchi et al., "Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment," Infection and Immunity 61:719-728 (1993)		
EXAMINER	DATE CONSIDERED 8/03		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			